Transcell Biologics: Financial Breakdown
Decoding financial health metrics of Transcell Biologics
Total Revenue₹4.0 Cr2%Prev. FY
Total Expenses₹7.3 Cr24%Prev. FY
Profit After Tax₹-3.2 Cr-58%Prev. FY
Total Assets₹4.4 Cr-42%Prev. FY
Net Profit Margin-80.3%-53%Prev. FY
FAQs on Financials of Transcell Biologics
No. In FY23, Transcell Biologics reported a net loss of ₹3.2 Cr, so it was not profitable.
Transcell Biologics's revenue grew 2.8% year-on-year, from ₹3.9 Cr in FY22 to ₹4.0 Cr in FY23.
Transcell Biologics's estimated EBITDA for FY23 was ₹-2.5 Cr, derived from its profit before tax, finance costs, and depreciation & amortisation.
In FY23, Transcell Biologics posted revenue of ₹4.0 Cr (up 2.8% YoY) and a net loss of ₹3.2 Cr. Explore the full financials of Transcell Biologics here...
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links